DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Short Bowel Syndrome (SBS) Market 2017-2021" report to their offering.
The global short bowel syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.
The report, Global Short Bowel Syndrome (SBS) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The latest trend gaining momentum in the market is increased awareness of GI disorders. Pharmaceutical companies and national and local government bodies such as the health ministry and municipalities are conducting programs to spread awareness of GI disorders. Many NGOs also conduct camps to educate people and raise the awareness level. Drug manufacturers supply visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This is done to increase the knowledge of the individuals about a particular GI disorder.
According to the report, one of the major drivers for this market is special drug designations. As the market is dominated by a few drugs and the pipeline also demonstrates the same, the special designation will provide more opportunity for revenue generation and to expand geographically. These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug's sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors to develop a product for a rare disease.
- Emmaus Medical
Other prominent vendors
- Naia Pharmaceuticals
- Sancilio Pharmaceuticals
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Orphan drug designation
PART 06: Pipeline landscape
PART 07: Market landscape
PART 08: Market segmentation by route of administration (ROA)
PART 09: Market segmentation by drug class
PART 10: Geographical segmentation
PART 11: Decision framework
PART 12: Drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
For more information about this report visit https://www.researchandmarkets.com/research/gzn9gm/global_short